L-DOPA

SKU: orb1310238

Description

Levodopa (L-DOPA) is an orally active dopamine precursor capable of crossing the blood-brain barrier. It is extensively used in Parkinson's disease research and modeling, and its anti-hyperalgesic properties are studied in both in vivo and in vitro pain research.

Research Area

Metabolism Research, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 59-92-7
• MW: 197.19
• Purity: 98.99% (May vary between batches)
• Formula: C₉H₁₁NO₄
• SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O
• Target: Endogenous Metabolite,Dopamine Receptor
• Solubility: H2O:2.5 mM;DMSO:Insoluble

Bioactivity

• In Vivo:
  Levodopa elicits the development of a variety of abnormal movements in monkeys with parkinsonism induced by the neurotoxin MPTP. Levodopa administrations result in an ectopic induction of the dopamine D3receptor expression in the CdPu in 6-OHDA-lesioned rats. Levodopa (50 mg/kg) increases anandamide concentrations throughout thebasal ganglia via activation of dopamine D1/D2 receptors in intact rats. Levodopa produces increasingly severe oro-lingual involuntary movements which are attenuated by the cannabinoid agonist R(+)-WIN55,212-2 (1 mg/kg) in lesioned rats. Levodopa administration reverses the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that Levodopa reaches a biologically active concentration at the basal ganglia.
• In Vitro:
  Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. Levodopa results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. Levodopa induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). Levodopa results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

precursor, Parkinson, neurotransmitters, Orally, L DOPA, inhibit, Levodopa, LDOPA, L-DOPA, Inhibitor, EndogenousMetabolite, Endogenous Metabolite, DopamineReceptor, Dopamine Receptor, Dopamine, dopamine, barrier, blood-brain, anti-allodynic, 3,4-Dihydroxyphenylalanine

Compound Identifiers

PubChem CID

6047